Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

RELIEF investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)476-486
Number of pages11
JournalThe Lancet Respiratory Medicine
Volume9
Issue number5
DOIs
StatePublished - May 2021

ASJC Scopus Subject Areas

  • Pulmonary and Respiratory Medicine

Cite this